ZoneOne Pharma

Executive Summary

ZoneOne Pharma (Z1P) is a private US biotechnology company developing novel topical liposomal therapies for chronic inflammatory skin diseases. Founded in 2018 and headquartered in New York, Z1P leverages proprietary liposomal drug delivery technologies to enhance the efficacy, safety, and compliance of existing and new chemical entities. The company's platform addresses significant unmet needs in dermatological conditions such as psoriasis, atopic dermatitis, and acne, where repeated topical applications often suffer from poor patient adherence and suboptimal pharmacokinetics. By engineering lipid-based nanocarriers, Z1P aims to achieve targeted skin deposition, reduced systemic exposure, and sustained release, potentially improving outcomes and quality of life for patients. While the company has not yet disclosed specific pipeline candidates or financial details, its strategic focus on dermatology—a large and growing market—positions it for potential partnerships or licensing deals with larger pharmaceutical firms.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2a clinical trial initiation for lead candidate in psoriasis60% success
• Q2 2026Publication of preclinical data in a peer-reviewed journal80% success
• H2 2026Research collaboration or licensing agreement with a top-20 pharma company40% success